

Have you **triple checked** your patients with COPD?

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β_2 -agonist or a combination of a long-acting β_2 -agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).^{1,2} Fostair pMDI and NEXThaler 100/6 are indicated for the symptomatic treatment of adult patients with severe COPD (FEV₁ <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.^{3,4}

Prescribing Information and Adverse Event reporting can be found at the end of this document.


UK-TRI-2500084 June 2025

Optimise care for your adult patients with moderate to severe COPD

According to GOLD recommendations, it is important to regularly monitor patients as this allows for a more tailored approach in effectively managing COPD.⁵

THE TRIPLE CHECK SYSTEM

Use the triple check system to identify which of your patients with moderate to severe COPD – currently treated with **ICS/LABA** or **ICS/LABA + LAMA via multiple inhalers** – could benefit from a single inhaler triple therapy.



Choose Trimbow, in either a pMDI or NEXThaler® (DPI), for your appropriate adult patients with moderate to severe COPD



Think triple (ICS/LABA/LAMA), Think Trimbow

Extrafine formulation like Fostair®
(beclometasone/formoterol)¹⁻⁴

Choice of device to help meet
your patients' needs^{1,2}

The Click of Confidence with NEXThaler for you
and your patients who need a DPI^{2,8}

- Confidence for your patients through confirmed dose delivery^{2,8}

A familiar pMDI device for your patients who need it^{1,9,10}

Trimbow pMDI 87/5/9 demonstrated:

- Similar rates of moderate to severe exacerbations vs. multiple inhalers (Fostair pMDI 100/6 + Spiriva® HandiHaler® [RR 1.01]) – secondary endpoint^{1,11}
- Reduction in moderate to severe exacerbations vs. ICS/LABA (Fostair pMDI 100/6) – secondary endpoint^{1,12*}



[Click here](#) or scan
to explore a range
of COPD patient
support materials
on ChiesiAir.co.uk



COPD: chronic obstructive pulmonary disease;
DPI: dry powder inhaler; **FEV₁:** forced expiratory volume in one second; **GOLD:** Global Initiative for Chronic Obstructive Lung Disease; **ICS:** inhaled corticosteroid; **LABA:** long-acting β_2 -agonist; **LAMA:** long-acting muscarinic antagonist; **N:** number of patients; **pMDI:** pressurised metered dose inhaler; **RR:** (adjusted) rate ratio; **SPC:** summary of product characteristics; **TDI:** Transition Dyspnea Index.

*Co-primary endpoints of TRILOGY: Superiority of Trimbow pMDI 87/5/9 vs. Fostair pMDI 100/6 was met in change from baseline in pre-dose morning FEV₁ (p<0.001), change from baseline in 2-h post-dose FEV₁ (p<0.001), but unmet for TDI focal score (p=0.160), all assessed at week 26 (N=1,368).¹² As one of the co-primary endpoints in the TRILOGY study did not achieve statistical significance, p-values shown for the TRILOGY study are descriptive.


Adverse events should be reported.
Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

References

1. Trimbow pMDI 87/5/9 Summary of Product Characteristics. Chiesi Limited.
2. Trimbow NEXThaler 88/5/9. Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025. Available at: <https://goldcopd.org/2025-gold-report/>.
6. NICE. Guideline NG115. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. Available at: <https://www.nice.org.uk/guidance/ng115/chapter/Recommendations>.
7. Kaplan A, Price D. *Can Respir J*. 2018; 9473051.
8. Voshaar T, et al. *J Aerosol Med Pulm Drug Deliv*. 2014; 27(5): 363–370.
9. LRX. R3F Group Data. Dec 2023.
10. IQVIA XBPI MAT. Dec 2023.
11. Vestbo J, et al. *Lancet*. 2017; 389(10082): 1919–1929.
12. Singh D, et al. *Lancet*. 2016; 388(10048): 963–973.



[Click here](#) or scan to view
Trimbow
Prescribing
Information



[Click here](#) or scan to view Fostair
Prescribing
Information